Post-effective Amendment to an S-8 Filing (s-8 Pos)

Date : 12/21/2018 @ 4:53PM
Source : Edgar (US Regulatory)
Stock : Endocyte, Inc. (delisted) (ECYT)
Quote : 23.99  0.0 (0.00%) @ 1:00AM
Endocyte, Inc. (delisted) share price Chart

Post-effective Amendment to an S-8 Filing (s-8 Pos)

As filed with the Securities and Exchange Commission on December 21, 2018

 

Registration No. 333-223314

Registration No. 333-216675

Registration No. 333-210035

Registration No. 333-202792

Registration No. 333-194366

Registration No. 333-190514

Registration No. 333-172121

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

POST-EFFECTIVE AMENDMENTS

TO

 

FORM S-8

 

REGISTRATION STATEMENTS

UNDER THE

SECURITIES ACT OF 1933

 


 

ENDOCYTE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

35-1969-140

(State or other jurisdiction of

 

(I.R.S. Employer

incorporation or organization)

 

Identification No.)

 

3000 Kent Avenue, Suite A1-100

West Lafayette, IN 47906

(Address of Principal Executive Offices) (Zip Code)

 

ENDOCYTE, INC. 2010 EQUITY INCENTIVE PLAN

ENDOCYTE, INC. 2010 EMPLOYEE STOCK PURCHASE PLAN

ENDOCYTE, INC. 2007 STOCK PLAN

ENDOCYTE, INC. 1997 STOCK PLAN

(Full title of the plan)

 

Michael A. Sherman

President and Chief Executive Officer

Endocyte, Inc.

3000 Kent Avenue, Suite A1-100

West Lafayette, IN 47906

(Name and address of agent for service)

 

(765) 463-7175

(Telephone number, including area code, of agent for service)

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

o

Accelerated filer

x

 

 

 

 

Non-accelerated filer

o

Smaller reporting company

o

 

 

 

 

Emerging growth company

o

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act . o

 

 

 


 

DEREGISTRATION OF SECURITIES

 

This Post-Effective Amendment (this “Post-Effective Amendment”) relates to the following registration statements of Endocyte, Inc. (the “Company”), each pertaining to the registration of the described number of shares of common stock of the Company offered under certain employee benefit and equity plans, originally filed on Form S-8 and as amended from time to time (collectively, the “Registration Statements”):

 

File No.

 

Date Originally Filed
with the SEC

 

Name of Equity Plan

 

Shares of
Common
Stock Initially
Registered

 

333-223314

 

February 28, 2018

 

Endocyte, Inc. 2010 Equity Incentive Plan

 

1,494,294

 

333-216675

 

March 14, 2017

 

Endocyte, Inc. 2010 Equity Incentive Plan

 

864,744

 

333-210035

 

March 9, 2016

 

Endocyte, Inc. 2010 Equity Incentive Plan

 

1,262,436

 

333-202792

 

March 16, 2015

 

Endocyte, Inc. 2010 Equity Incentive Plan

 

1,677,644

 

333-202792

 

March 16, 2015

 

Endocyte, Inc. 2010 Employee Stock Purchase Plan

 

417,000

 

333-194366

 

March 6, 2014

 

Endocyte, Inc. 2010 Equity Incentive Plan

 

1,446,000

 

333-194366

 

March 6, 2014

 

Endocyte, Inc. 2010 Employee Stock Purchase Plan

 

361,000

 

333-190514

 

August 9, 2013

 

Endocyte, Inc. 2010 Equity Incentive Plan

 

2,865,365

 

333-172121

 

February 9, 2011

 

Endocyte, Inc. 2010 Equity Incentive Plan

 

1,498,929

 

333-172121

 

February 9, 2011

 

Endocyte, Inc. 2010 Employee Stock Purchase Plan

 

261,780

 

333-172121

 

February 9, 2011

 

Endocyte, Inc. 2007 Stock Plan

 

1,519,654

 

333-172121

 

February 9, 2011

 

Endocyte, Inc. 1997 Stock Plan

 

476,640

 

 

As previously disclosed, on October 17, 2018, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Novartis AG, a company organized under the laws of Switzerland (“Novartis”), and Edinburgh Merger Corporation, a Delaware corporation and a wholly owned subsidiary of Novartis (“Merger Sub”). Pursuant to the Merger Agreement, on December 21, 2018, Merger Sub was merged with and into Endocyte (the “Merger”), with Endocyte continuing as the surviving corporation and a wholly owned subsidiary of Novartis.

 

As a result of the Merger, the Company has terminated all offerings of its securities pursuant to the Registration Statements. In accordance with the undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered pursuant to the Registration Statements which remain unsold at the termination of the offerings, the Company hereby removes from registration all such securities as of the date of this Post-Effective Amendment. Each of the Registration Statements is hereby amended, as appropriate, to reflect the deregistration of all such securities.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in West Lafayette, Indiana, on December 21, 2018.

 

 

Endocyte, Inc.

 

 

 

 

 

By:

/s/ Michael A. Sherman

 

 

Michael A. Sherman,

 

 

President and Chief Executive Officer

 

No other person is required to sign this Post-Effective Amendment to the Registration Statements in reliance on Rule 478 of the Securities Act of 1933, as amended.

 

3


Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart

1 Year : From Jun 2018 to Jun 2019

Click Here for more Endocyte, Inc. (delisted) Charts.

Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Intraday Stock Chart

Today : Wednesday 19 June 2019

Click Here for more Endocyte, Inc. (delisted) Charts.

Latest ECYT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20190619 09:45:01